Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?
C.T. Leonard, Nick Crabb, David M. Glover, et al.
Applied Health Economics and Health Policy (2023) Vol. 21, Iss. 3, pp. 365-372
Open Access | Times Cited: 17

Showing 17 citing articles:

Antibiotics in the clinical pipeline as of December 2022
Mark S. Butler, Ian R. Henderson, Robert J. Capon, et al.
The Journal of Antibiotics (2023) Vol. 76, Iss. 8, pp. 431-473
Open Access | Times Cited: 129
Global Strategies to Combat Antimicrobial Resistance: A One Health Perspective
Steward Mudenda, Billy Chabalenge, Victor Daka, et al.
Pharmacology & Pharmacy (2023) Vol. 14, Iss. 08, pp. 271-328
Open Access | Times Cited: 48
A Review of Antibacterial Candidates with New Modes of Action
Mark S. Butler, Waldemar Vollmer, Emily C. A. Goodall, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 10, pp. 3440-3474
Open Access | Times Cited: 16
Small-Molecule Antibiotic Drug Development: Need and Challenges
Megan Bergkessel, Barbara Forte, Ian H. Gilbert
ACS Infectious Diseases (2023) Vol. 9, Iss. 11, pp. 2062-2071
Open Access | Times Cited: 30
Tracking progress on antimicrobial resistance by the quadripartite country self-assessment survey (TrACSS) in G7 countries, 2017–2023: opportunities and gaps
Michela Sabbatucci, Diane Ashiru‐Oredope, Laura Barbier, et al.
Pharmacological Research (2024) Vol. 204, pp. 107188-107188
Open Access | Times Cited: 9
Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward
Thomas Tängdén, Elena Carrara, Mona Mustafa Hellou, et al.
Clinical Microbiology and Infection (2024)
Closed Access | Times Cited: 5
The Burden of Antimicrobial Resistance in Zambia, a Sub-Saharan African Country: A One Health Review of the Current Situation, Risk Factors, and Solutions
Steward Mudenda, Webrod Mufwambi, Shafiq Mohamed
Pharmacology & Pharmacy (2024) Vol. 15, Iss. 12, pp. 403-465
Open Access | Times Cited: 5
Reforming the innovation system to deliver affordable medicines: a conceptual framework of pharmaceutical innovation as a complex adaptive system (forest) and theory of change
Suerie Moon, Adrián Alonso Ruiz, Marcela Vieira, et al.
Journal of Pharmaceutical Policy and Practice (2025) Vol. 18, Iss. 1
Open Access
Global Pull Incentives for Better Antibacterials: The UK Leads the Way
Kevin Outterson, John Rex
Applied Health Economics and Health Policy (2023) Vol. 21, Iss. 3, pp. 361-364
Open Access | Times Cited: 8
Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review
Vittoria Ardito, Ludovico Cavallaro, Michael Drummond, et al.
PharmacoEconomics - Open (2024) Vol. 8, Iss. 5, pp. 765-772
Open Access | Times Cited: 2
Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally
Sabine Vogler, Katharina Habimana, Manuel Alexander Haasis, et al.
Applied Health Economics and Health Policy (2024) Vol. 22, Iss. 5, pp. 629-652
Closed Access | Times Cited: 1
Design and Features of Pricing and Payment Schemes for Health Technologies: A Scoping Review and a Proposal for a Flexible Need-Driven Classification
Vittoria Ardito, Oriana Ciani, Michael Drummond
PharmacoEconomics (2024)
Open Access | Times Cited: 1
Move over COVID, Tuberculosis Is Once again the Leading Cause of Death from a Single Infectious Disease
Tomayo Berida, Craig W. Lindsley
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 24, pp. 21633-21640
Closed Access | Times Cited: 1
Improving health evaluations to capture wider value of therapeutics and incentivise innovation
Mei Sum Chan, Jack C. Kowalik, Tom Ashfield, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 2
Improving antibiotic prescribing – Recommendations for funding and pricing policies to enhance use of point-of-care tests
Sabine Vogler, Caroline Steigenberger, Friederike Windisch
Health Policy OPEN (2024) Vol. 7, pp. 100129-100129
Open Access
Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England
Beth Woods, Benjamin Kearns, Laëtitia Schmitt, et al.
Applied Health Economics and Health Policy (2024) Vol. 23, Iss. 1, pp. 5-17
Closed Access
Netflix and pill: is there a role for volume-delinked subscription-style payments beyond antimicrobials?’
Grace Hampson, Lotte Steuten
Expert Review of Pharmacoeconomics & Outcomes Research (2023) Vol. 24, Iss. 1, pp. 1-3
Open Access | Times Cited: 1
Page 1

Scroll to top